Corporate Team
VP, Regulatory Affairs - Martin Wang, Ph.D
Dr. Wang has been actively involved in the regulatory compliance and research and development of phytopharmaceuticals and nutraceutical products in the past 20 years. He is an expert in the licensing of Canada NHP and US FDA botanical drug IND or food supplement as well as China SFDA novel drug applications. Prior to PLC, Dr. Wang worked as the Director of Regulatory affairs for Pegasus Pharmaceutical Group Inc. Dr. Wang also has extensive experience in novel drug research from screening natural products as drug candidates to translational studies of investigational drugs as well as formulation, pilot-scale development, chromatographic fingerprinting profiles of finished botanical products, and quality control. He was a Research Associate in the Cross Cancer Institute of University of Alberta and a Senior Analyst in the Division of Food and Natural Health Product (NHP), ALS Laboratory Group, Edmonton. Before coming to Canada, Dr. Wang was an Associate Professor in the School of Pharmacy, Nanjing University of Traditional Chinese Medicine, China. Concurrently he also served as the Deputy Director of the Jiangsu Provincial Centre for Quality Control of Chinese Medicine. Dr. Wang received his doctoral degree from the Nanjing University of Traditional Chinese Medicine, China and finished his post-doctoral research in the Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Japan and then in Jinling Pharmaceutical Company, Nanjing, China. Dr. Wang has over 50 publications in peer-reviewed journals and 3 patents of novel botanical drugs in China.
Fred Mu, MSc.
Mr. Mu has over 20 years of working experience as QC, QA, Manufacturing and R&D in the pharmaceutical and Nutraceutical industry in Canada, Japan and China. Prior to PLC, Mr. Mu worked as the QC QA Manager for an international pharmaceuticals company and as QA and Manufacture Supervisor for Organika Health Products Inc. and Capwork Nutrition Ltd. From 1989 to 2006, Mr. Mu was the QC, QA, R&D Manager in Qingdao Huazhong Pharmaceuticals Ltd., an affiliated company of Kanebo Pharmaceuticals Inc. of Japan. Mr. Mu received his Master of Science from College of Pharmacy, Fudan University, China.
Chemistry Scientist - Joshua Yu, Ph.D,
Dr. Joshua Yu received his doctoral degree from the University of Göttingen, Germany. He continued his post-doctoral research in the University of British Columbia (UBC), Canada. Dr. Yu has over 20 years of research experience in extraction and purification of active phytomedicinal compounds from herbs, modification of structure of the active molecules from herbs, and synthesis of small molecule compounds, Bioinorganic Chemistry, Organometallics and Nano-Cluster material Chemistry. Dr. Yu has published over 20 academic papers on various world renowned journals and magazines and had applied several technology patents.
Clinical Director - Sherman Zhao, MD, Ph.D
Dr. Sherman Zhao graduated from the Shanghai Medical University with a bachelor's degree in laboratory medicine. At the Peking University, he received his doctoral degree in Pharmacology. When Dr. Zhao was later studying in the Georgia State University, United States, he completed his post-doctoral research. Prior to joining PLC, Dr. Zhao has gained profound knowledge and clinical experience in treating cancer and Alzheimer’s disease and has published over 10 papers. He has also been engaged in the research and development of novel drugs in domestic and foreign pharmaceutical companies. Dr. Zhao was the key person involved in the development of two phytopharmaceuticals which were approved for clinical trial in 2005, and is the principal investigator of the undergoing Phase III clinical trial.
Scientific Advisor - Dr. William Campbell, Ph.D.
Dr. William Campbell, Ph.D. has over 45 years of experience in the field of protein chemistry. In 1989, while in Japan as an associate professor at Nagoya City University he discovered a novel enzyme, carboxypeptidase R, an important regulator of inflammation and fibrinolysis and was a leading SARS researcher.
Over the past several years he has made use of novel computer algorithms that create peptide antibody mimetics to targets in proteins and has used peptide array technology to identify potential drug candidates for both therapeutic and diagnostic applications.
After leaving Japan, Dr. Campbell spent two years as visiting scientist at the Kinsmen Laboratory of Neurological Research at the University of British Columbia before starting several biotech companies specialized in research and development of peptide drugs and natural health products.
Scientific Advisor - Dr. William Jia, Ph.D.
Dr. William Jia is Associate Professor at University of British Columbia and Senior Scientist at BC Cancer Research Centre. He is also a prestigious Canadian Institute of Health Research (CIHR) Scholar. He has 31 peer reviewed publications on the brain and/or cancer. Dr. Jia leads the Company's research programs.